Agenus Secures Up to $340 Million to Advance Neoadjuvant BOT+BAL in MSS Colon Cancer, Pivoting Away from Metastatic Setting
核心洞察
Agenus announced an oversubscribed private placement of up to $340 million, with $85 million upfront and up to $255 million upon full warrant exercise, to fund the registrational Phase 3 ROBBIN trial.
The ROBBIN trial will evaluate neoadjuvant botensilimab plus balstilimab (BOT+BAL) in high-risk Stage II/III microsatellite-stable (MSS) colon cancer, a population with no new curative-intent therapies approved in over 20 years.
Phase 2 data from NEST and UNICORN trials showed pathologic complete response rates of approximately 30% and major pathologic response rates of 35-40%, with all treated patients remaining disease free at median follow-up of 9 to 18 months.
Agenus Inc. announced on July 13, 2026, that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, with up to an additional $255 million upon full exercise of purchase warrants, for a combined total of up to $340 million. The financing, led by Commodore Capital (搜索) with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals, is expected to fund the company through key value-inflection points in its registrational Phase 3 ROBBIN trial, with runway through year-end 2031 assuming full warrant exercise.
The net proceeds will support Agenus' strategic prioritization of botensilimab (BOT) and balstilimab (BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer. The private placement is expected to close on or about July 15, 2026, subject to customary closing conditions, with all pricing set at a premium to the market closing price as of July 10, 2026.
A Large Unmet Need in MSS Colon Cancer
High-risk Stage II and Stage III MSS colon cancer affects an estimated 38,000 patients annually in the United States and more than 200,000 patients worldwide. The addressable annual sales opportunity in the US is estimated at more than $7 billion, with no new curative-intent therapies approved in more than 20 years. MSS colon cancer has historically been considered a "cold" tumor that resists standard checkpoint inhibitors, leaving a significant gap in the treatment landscape.
Compelling Phase 2 Data Drive Strategic Pivot
Across two independent Phase 2 studies — NEST and UNICORN — evaluating neoadjuvant BOT+BAL in MSS colorectal cancer, the combination produced deep and durable responses. Pathologic response was observed in approximately 60-70% of patients, major pathologic response (MPR) in approximately 35-40%, and pathologic complete response (pCR) in approximately 30%. With median follow-up of approximately 9 to 18 months, all treated patients remained disease free. The treatment effect has persisted in updates from both studies, and further details are anticipated to be published later this year.
Deep pathologic responses, including MPR and pCR, are positively correlated with event-free survival in many tumor types, including MSS colon cancer. Additionally, observed circulating tumor DNA (ctDNA) clearance during treatment further supports the rationale for advancing BOT+BAL into the registrational setting.
"We have seen neoadjuvant and perioperative immunotherapy improve outcomes in immunologically 'hot' or 'warm' tumors such as melanoma and lung cancer, but MSS colon cancer — a 'cold' tumor — has resisted standard checkpoint inhibitors," said Dr. Steven O'Day, Chief Medical Officer of Agenus. "BOT was engineered to overcome that resistance and has produced deep pathologic responses with no recurrences reported in the NEST and UNICORN studies."
The ROBBIN Phase 3 Trial Design
ROBBIN is Agenus' planned randomized, open-label, global Phase 3 trial evaluating neoadjuvant BOT+BAL followed by standard of care versus standard of care alone in previously untreated high-risk Stage II and Stage III MSS/pMMR colon cancer. The trial will enroll 850 patients randomized 1:1, with event-free survival (EFS) as the primary endpoint.
Following interactions with the US Food and Drug Administration, Agenus has aligned with the agency on key elements of the Phase 3 design, including the patient population, experimental regimen, control arm, primary endpoint, and interim analysis plan. Key secondary and exploratory endpoints are expected to include overall survival, circulating tumor DNA negativity, quality of life, safety, and pathologic response.
The proposed design includes neoadjuvant BOT+BAL followed by surgery and guideline-directed adjuvant chemotherapy or observation based on pathologic staging, compared with the current standard of care of surgery followed by guideline-directed adjuvant chemotherapy or observation.
Discontinuation of BATTMAN Trial
In connection with its strategic prioritization, Agenus plans to discontinue financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. The company will honor its obligations to patients currently receiving treatment and will work closely with the Canadian Cancer Trials Group (CCTG) and participating investigators to manage the transition responsibly.
"Since Agenus was founded 32 years ago, our mission has been to harness the immune system to improve outcomes and, where possible, cure cancer," said Garo H. Armen, Ph.D., Founder, Chairman and Chief Executive Officer of Agenus. "Our plan to prioritize neoadjuvant BOT+BAL in MSS colon cancer reflects both the strength of the emerging clinical evidence and the opportunity to bring this important combination regimen to patients where it may have the greatest impact."
Upcoming Milestones
Agenus has outlined several anticipated catalysts for the ROBBIN program: first patient dosed in Q1 2027, interim pathologic response data in the second half of 2027, interim analysis of EFS in the second half of 2029, and final analysis of EFS in the second half of 2030.
About Botensilimab and Balstilimab
Botensilimab is a human Fc-enhanced multifunctional anti-CTLA-4 (搜索) antibody designed to boost both innate and adaptive anti-tumor immune responses, extending immunotherapy benefits to "cold" tumors that generally respond poorly to standard of care. Balstilimab is a fully human monoclonal IgG4 antibody designed to block PD-1 (搜索) from interacting with its ligands PD-L1 and PD-L2. Approximately 1,300 patients have been treated with BOT and/or BAL in Phase 1 and Phase 2 clinical trials, with clinical responses observed across nine metastatic, late-line cancers.